Optilume BPH Catheter System in Benign Prostatic Hyperplasia (BPH)

NCT05567666 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-10-05

No results posted yet for this study

Summary

A post-marketing study using Optilume Catheter System for benign prostatic hyperplasia.

Conditions

  • Benign Prostatic Hyperplasia

Interventions

DEVICE

Optilume Catheter System

Optilume Catheter System, which is a Dilation Drug Coated Balloon (DCB) Catheter

Sponsors & Collaborators

  • Urotronic Inc.

    collaborator INDUSTRY
  • Dean Elterman

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-15
Primary Completion
2024-12-31
Completion
2024-12-31
FDA Device
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05567666 on ClinicalTrials.gov